-2.45 %
-2.35 %
+0.63 %
-74.50 %
-76.05 %
-78.43 %
-83.88 %
-89.22 %
-85.68 %
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreMarket cap
108.93M EUR
Turnover
215.62K EUR
P/E (adj.) (26e)
-4.63
EV/EBIT (adj.) (26e)
-5.33
P/B (26e)
82.95
EV/S (26e)
25,317.49
Dividend yield-% (26e)
-
